Medisys PLC (MDY) Providing innovative solutions to the rapidly growing point-of-care diagnostic and healthcare worker safety markets. For more than 35 years, companies in the Medisys group have been advancing healthcare through development, manufacture and distribution of revolutionary medical products. The Group's mission is to become a leading worldwide provider of diagnostic systems and medical safety products enabling rapid, cost effective, on-site delivery of healthcare solutions.
For more than three decades, Medisys' primary operating unit, Hypoguard, has been devoted to advancing personal and professional healthcare management. The Company's core focus is diabetes glucose self-monitoring - a rapidly growing market of nearly $5 billion worldwide.
'Medisys-group.com'
'Hypoguard.com'

15/02/2006
Medisys reported a 'considerable improvement' in trading during the first four months of its financial year, and said the business has been cash-flow neutral for the year to date.
The medical products company said competition in its core long-term care blood glucose monitoring business has not intensified. A drop in sales amid intense competition in the market caused a fall in sales and profits last year.
Sales volumes have recovered to previous highs by cutting prices and offering various promotions, Medisys reported this morning.
Margin improvements have been achieved faster than originally anticipated, it added. The company has benefited from cost saving measures implemented in the second half of the last financial year and cost reductions for its proprietary biosensor products.
Meanwhile, it has completed the development and manufacturing scale up of the first of the new systems it has designed for Menarini, the fifth largest worldwide branded marketer of blood glucose monitoring systems.
While the launch date is not yet clear, (Around March 1) Medisys predicted that sales of the products will be one of its key revenue growth drivers in the current financial year.


LATEST ON MDY V'S ROCHE COURT CASE
MDY V'S ROCHE COURT CASE Case IS Dismissed. http://www.moneyam.com/InvestorsRoom/posts.php?tid=8721#lastread
My apologies for any one that was on MDY it looks like we have been stitched up like a kipper the sale of Hypoguard blood glucose monitoring business at that price looks like an sp of 3p against the close of 6.4p what can I say no one could have seen this coming a total sell out and that is what I have done.

hangon
Like you say with some stocks you can only hang on and hope as with my pcm good luck I will keep an eye on it any way.

The Company received notification on 3 January 2007 that on 3 January 2007 Charles Spicer, Chief Executive of the Company, purchased 1,000,000 ordinary shares of 1p each in the Company at a price of 2.35p per share. As a result of this transaction Mr Spicer has a beneficial interest in 8,166,666 ordinary shares in the Company representing 1.17 per cent of the issued share capital of that class.

The Company also received notification on 3 January 2007 that on 3 January 2007 David Wong, Executive Chairman of the Company, purchased 408,347 ordinary shares of 1p each in the Company at a price of 2.35p per share. As a result of this transaction Mr Wong has a beneficial interest in 37,075,013 ordinary shares in the Company representing 5.30 per cent of the issued share capital of that class.

The Company also received notification on 3 January 2007 that on 3 January 2007 Derek Ablett, Non-Executive Director of the Company, purchased 163,265 ordinary shares of 1p each in the Company at a price of 2.35p per share. As a result of this transaction Mr Ablett has a beneficial interest in 263,403 ordinary shares in the Company representing 0.04 per cent of the issued share capital of that class.


ENDS

Been a long time since Wong dipped his hand in his pocket and purchased stock.